Company intelligence / Profile preview

Rizobacter

Pergamino, Buenos Aires, Argentina

Ownership: Private
Employees: ~620
Development stage: Other

Overview

Rizobacter has more than four decades of positive results in agricultural biologicals, holding 23% of the global soybean inoculant market and ranking among the top five biological input suppliers. Newer products like Rizoderma showed efficacy in suppressing major crop diseases, and their inoculants can be applied 220 days pre-planting

Therapeutic areas: OtherInfectious Diseases
Modalities: Microbial therapyLive biotherapeutic product therapyBiologicProtein (enzymes, microbial extracts)Fungi-based biologic
Industry: Agriculture & AgTech

Partnerships

Strong collaborations with technical-scientific institutions, distributors, and manufacturers

Beyond the preview

Go deeper on Rizobacter.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rizobacter.

Explore the full profile